Cost-utility analysis of dapagliflozin for the treatment of symptomatic chronic heart failure in Spain
Abstract Background The objective of this study was to perform a cost-utility analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), compared with SoC, for patients with symptomatic chronic heart failure (HF) in Spain, including patients with reduced and preserved ejection fracti...
Saved in:
| Main Authors: | Carlos Escobar, Domingo Pascual-Figal, Josep Maria Guiu-Segura, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12913-025-13089-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
by: Huiyuan Zhang, et al.
Published: (2025-07-01) -
COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN
by: V. I. Petrov, et al.
Published: (2016-04-01) -
Cost-effectiveness of dapagliflozin for the treatment of heart failure: a systematic review
by: Zehui Jiang, et al.
Published: (2025-05-01) -
Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis
by: Juan Francisco Navarro-González, et al.
Published: (2024-11-01) -
Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain
by: Oriol Rodríguez-Leor, et al.
Published: (2024-11-01)